GPIb Alpha Binding Compounds for NASH and HCC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are inadequate, and there is a lack of effective therapies for late-stage NASH-induced hepatocellular carcinoma (HCC), primarily due to the insufficient understanding of the chronic inflammatory and metabolic mechanisms underlying these conditions, leading to limited therapeutic options with significant side effects.
Innovation Solution
The development of compounds that specifically bind to the ectodomain of platelet glycoprotein Ib (GPIb), impairing the interaction with thrombin, thereby reducing the progression of NAFLD, NASH, and associated conditions such as HCC, through the use of pharmaceutical compositions and methods involving antibody-like molecules and antigenic binding fragments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for NAFLD/NASH, then liver disease progression is addressed, but significant side effects occur and therapeutic effectiveness is limited
Solution Approach 1:
The patent uses GPIb ectodomain binding compounds as intermediary molecules that specifically target the thrombin-GPIb interaction pathway. These compounds act as mediators between the therapeutic goal (reducing liver inflammation and fibrosis) and the biological system, blocking platelet activation and thrombin signaling without causing the broad side effects of conventional treatments. The specific binding to GPIb ectodomain provides selective intervention in the disease pathway.
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific anti-inflammatory or antifibrotic approaches to specific targeting of the GPIb-thrombin interaction. By altering the mechanism of action to focus on platelet-GPIb binding inhibition, the treatment achieves better therapeutic effectiveness while reducing side effects through parameter-specific intervention rather than broad-spectrum therapy.
2Reliability
If the mechanisms underlying NAFLD/NASH are not understood, then treatment development is hindered, but research time and resources are consumed
Solution Approach 1:
The patent applies preliminary action by first elucidating the chronic inflammatory and metabolic mechanisms underlying NAFLD/NASH progression, particularly the role of platelet-GPIb-thrombin interactions. This preliminary mechanistic understanding is established before developing specific therapeutics, allowing for more efficient and successful treatment development. The screening methods and mechanism elucidation are performed in advance to guide subsequent therapeutic development.
3Adaptability or versatility
If existing therapeutic options are used, then some liver disease symptoms are managed, but late-stage NASH-induced HCC lacks effective treatment
Solution Approach 1:
The GPIb ectodomain binding compounds exhibit multi-functionality by addressing multiple aspects of liver disease pathogenesis through a single mechanism. The compounds can prevent early-stage NAFLD progression, treat intermediate NASH, and potentially address late-stage HCC by blocking platelet activation and thrombin signaling pathways that are involved throughout disease progression. This universal approach provides treatment coverage across different disease stages.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce liver damage, intrahepatic inflammation, immune cell infiltration, steatosis, and fibrosis, while preventing the progression of NAFLD and NASH to cirrhosis and HCC, offering a new therapeutic strategy with reduced side effects.
Implementation Method 1
a specific binding of compounds to the ectodomain of platelet glycoprotein Ib (GPIb) alpha reduces the occurrence and progression of non-alcoholic fatty liver disease (NAFLD)
Data Source
Figure 1
Figure 2A~2G
Figure 3a~3f
AI summary
The disclosure is based on the finding that a specific binding of compounds to the ectodomain of platelet glycoprotein Ib (GPIb) alpha reduces the occurrence and progression of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), or of a disorder or condition associated with NAFLD or NASH, such as a disorder or condition developing from NAFLD or NASH (such as Hepatocellular Carcinoma). The disclosure provides treatment options of NAFLD/NASH and HCC patients based on the specific binding to the GPIb ectodomain, and preferably by impairing GPIb-thrombin interaction. The disclosure further proposes medical treatments as well screening methods for the identification of compounds suitable for the treatment of NAFLD/NASH and HCC.